drugset / Trial / NCT03822975

Bivalirudin With Prolonged Full Dose Infusion Versus Heparin Alone During Emergency PCI

NCT03822975

Completed 6016 enrolled Shenyang Northern Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

This study is aimed to investigate if the bivaliruding with prolonged full dose infusion after PCI is superior to heparin alone in reducing 30-day mortality or major bleeding for patients with STEMI treated with emergency PCI. A total of 6000 STEMI patients will be enrolled and randomly assigned to receive bivalirudin or heparin during emergency PCI in a 1:1 ratio. This study will provide key evidence for peri-operative anticoagulant therapy decisions in STEMI patients.

Timeline

Start
2019-02-14
Primary completion
2022-05-07
Completion
2023-05-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Bivalirudin Peptide 1.75 mg/kg Intravenous
Comparator Heparin Other / unclassified 70 iu/kg Intravenous